Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 2/20 | 0.44 |
| ▸ | XBP1 | P17861 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | CD44 | P16070 | 1/20 | 0.40 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31418282 | 0.86 | MAPT (0.45) | MAPTPOLBMEN1ALOX15KMT2A | |
| SCHEMBL17942847 | 0.84 | MAPT (0.44) | MAPTPOLBMEN1ALOX15KMT2A | |
| SCHEMBL463283 | 0.76 | PLAU (0.55) | MEN1KMT2AHSD17B10ALDH1A1KDM4E | |
| SCHEMBL4871533 | 0.74 | TSHR (0.46) | MAPTMEN1KMT2AHSD17B10PDE3B | |
| SCHEMBL862522 | 0.72 | PDE3B (0.47) | MAPTPOLBMEN1ALOX15KMT2A | |
| SCHEMBL7048517 | 0.71 | NCF1 (0.59) | LMNANOS3NOS1NOS2 | |
| SCHEMBL19343131 | 0.71 | KDM4E (0.44) | MAPTPOLBMEN1ALOX15KMT2A | |
| SCHEMBL9732163 | 0.69 | DRD4 (0.53) | MAPTPOLBMEN1KMT2APDE3B | |
| SCHEMBL1188539 | 0.69 | ALDH1A1 (0.56) | MAPTPOLBMEN1KMT2AHSD17B10 | |
| SCHEMBL16148387 | 0.69 | CCR1 (0.59) | MAPTALOX15USP2HSD17B10ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390819-B2 | Imidazo[4,5-b]quinoline-derivatives and their use as no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2008-06-24 | — | — | US | disclosed |
| EP-1599473-B1 | IMIDAZO 4,5-B QUINOLINE-DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2006-09-20 | — | — | EP | disclosed |
| US-20060160839-A1 | Imidazo[4,5-b]quinoline-derivatives and their use as no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2006-07-20 | — | — | US | disclosed |
| CN-1751043-A | Imidazo[4,5-b]quinoline-derivatives and their use as no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2006-03-22 | — | — | CN | disclosed |
| EP-1599473-A1 | IMIDAZO 4,5-B QUINOLINE-DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | ALTANA Pharma AG (DE) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004076451-A1 | IMIDAZO[4,5-B]QUINOLINE-DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160839-A1 | Imidazo[4,5-b]quinoline-derivatives and their use as no-synthase inhibitors | NOS2, NOS1, NOS3 | MAPT 4210/4885POLB 1556/4885MEN1 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.